Mutant TP53 posttranslational modifications: Challenges and opportunities

Human Mutation

Volumn 35, Issue 6, 2014, Pages 738-755

  Nguyen, Thuy Ai ^a   Menendez, Daniel ^a   Resnick, Michael A ^a   Anderson, Carl W ^a,b  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

Acetylation; Methylation; P53; Phosphorylation; TP53; Transcription; Ubiquitylation

Indexed keywords

ACYLTRANSFERASE; BINDING PROTEIN; E1A ASSOCIATED P300 PROTEIN; ISOMERASE; LYSINE; PROLINE ISOMERASE 1; PROTEIN MDM2; PROTEIN P53; SERINE; SMAD PROTEIN; THREONINE; TIP60 PROTEIN; TRANSCRIPTION FACTOR 53BP1; TRANSCRIPTION FACTOR L3MBTL1; TRANSCRIPTION FACTOR PHF20; UNCLASSIFIED DRUG; TP53 PROTEIN, HUMAN;

ACETYLATION; CANCER INHIBITION; CARCINOGENESIS; GAIN OF FUNCTION MUTATION; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; METHYLATION; MUTATION; NEOPLASM; PATHOLOGY; PHOSPHORYLATION; UBIQUITINATION;

ACETYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METHYLATION; MUTATION; NEOPLASMS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION;

EID: 84901240407     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22506     Document Type: Review

References (179)

1. Acs K, Luijsterburg MS, Ackermann L, Salomons FA, Hoppe T, Dantuma NP. 2011. The AAA-ATPase VCP/p97 promotes 53BP1 recruitment by removing L3MBTL1 from DNA double-strand breaks. Nat Struct Mol Biol 18:1345-1350.
2. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, Solari A, Bobisse S, Rondina MB, Guzzardo V, Parenti, AR, Rosato, A, et al. 2009. A mutant-p53/Smad complex opposes p63 to empower TGFβ-induced metastasis. Cell 137:87-98.
3. Anderson CW, Appella E. 2009. Signaling to the p53 tumor suppressor through pathways activated by genotoxic and non-genotoxic stresses. In: Bradshaw RA, Dennis EA, editors. Handbook of cell signaling. Elsevier, San Diego, CA. p 2185-2204.
4. 18 is required for p53-mediated tumor suppression. Cancer Res 67:11696-11703.
5. Armata HL, Golebiowski D, Jung DY, Ko HJ, Kim JK, Sluss HK. 2010. Requirement of the ATM/p53 tumor suppressor pathway for glucose homeostasis. Mol Cell Biol 30:5787-5794.
6. Badeaux AI, Shi Y. 2013. Emerging roles for chromatin as a signal integration and storage platform. Nat Rev Mol Cell Biol 14:211-224.
7. Bar JK, Slomska I, Rabczyńki J, Noga L, Gryboś M. 2009. Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors. Int J Gynecol Cancer 19:1322-1328.
8. Bartkova J, Hořejší Z, Sehested M, Nesland JM, Rajpert-De Meyts E, Skakkebæk NE, Stucki M, Jackson S, Lukas J, Bartek J. 2007. DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene 26:7414-7422.
9. Bech-Otschir D, Kraft R, Huang X, Henklein P, Kapelari B, Pollmann C, Dubiel W. 2001. COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J 20:1630-1639.
10. Bensimon A, Aebersold R, Shiloh Y. 2011. Beyond ATM: the protein kinase landscape of the DNA damage response. FEBS Lett 585:1625-1639.
11. Berger M, Stahl N, Del Sal G, Haupt Y. 2005. Mutations in proline 82 of p53 impair its activation by Pin1 and Chk2 in response to DNA damage. Mol Cell Biol 25:5380-5388.
12. Bode AM, Dong Z. 2004. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4:793-805.
13. Brooks CL, Gu W. 2003. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 15:164-171.
14. Brosh R, Rotter V. 2009. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9:701-713.
15. Bruins W, Zwart E, Attardi LD, Iwakuma T, Hoogervorst EM, Beems RB, Miranda B, van Oostrom CTM, van den Berg J, van den Aardweg GJ, Lozano G, van Steeg H, et al. 2004. Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol Cell Biol 24:8884-8894.
16. Burns TF, Fei P, Scata KA, Dicker DT, El-Deiry WS. 2003. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol 23:5556-5571.
17. Campaner S, Spreafico F, Burgold T, Doni M, Rosato U, Amati B, Testa G. 2011. The methyltransferase Set7/9 (Setd7) is dispensable for the p53-mediated DNA damage response in vivo. Mol Cell 43:681-688.
18. Carr SM, Munro S, La Thangue NB. 2012. Lysine methylation and the regulation of p53. Essays Biochem 52:79-92.
19. Carter S, Vousden KH. 2009. Modifications of p53: competing for the lysines. Curr Opin Genet Dev 19:18-24.
20. 18 phosphorylation in regulating p53 responses. J Biol Chem 278:41028-41033.
21. Chao C, Herr D, Chun J, Xu Y. 2006a. Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO J 25:2615-2622.
22. Chao C, Wu Z, Mazur SJ, Borges H, Rossi M, Lin T, Wang JYJ, Anderson CW, Appella E, Xu Y. 2006b. Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol Cell Biol 26:6859-6869.
23. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346-355.
24. Christophorou MA, Ringshausen I, Finch AJ, Swigart LB, Evan GI. 2006. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443:214-217.
25. Coffill CR, Muller PAJ, Oh HK, Neo SP, Hogue KA, Cheok CF, Vousden KH, Lane DP, Blackstock WP, Gunaratne J. 2012. Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion. EMBO Rep 13:638-644.
26. Collavin L, Lunardi A, Del Sal G. 2010. p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ 17:901-911.
27. Cordenonsi M, Montagner M, Adorno M, Zacchigna L, Martello G, Mamidi A, Soligo S, Dupont S, Piccolo S. 2007. Integration of TGF-β and Ras/MAPK signaling through p53 phosphorylation. Science 315:840-843.
28. Cui G, Park S, Badeaux AI, Kim D, Lee J, Thompson JR, Yan F, Kaneko S, Yuan Z, Botuyan MV, Bedford MT, Cheng JQ, et al. 2012. PHF20 is an effector protein of p53 double lysine methylation that stabilizes and activates p53. Nat Struct Mol Biol 19:916-924.
29. Dai C, Gu W. 2010. p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med 16:528-536.
30. Dai C, Shi D, Gu W. 2013. Negative regulation of the acetyltransferase TIP60-p53 interplay by UHRF1 (ubiquitin-like with PHD and RING Finger Domains 1). J Biol Chem 288:19581-19592.
31. Dai C, Tang Y, Jung SY, Qin J, Aaronson SA, Gu W. 2011. Differential effects on p53-mediated cell cycle arrest vs. apoptosis by p90. Proc Natl Acad Sci U S A 108:18937-18942.
32. Debnath S, Chatterjee S, Arif M, Kundu TK, Roy S. 2011. Peptide-protein interactions suggest that acetylation of lysines 381 and 382 of p53 is important for positive coactivator 4-p53 interaction. J Biol Chem 286:25076-25087.
33. Dehart CJ, Chahal JS, Flint SJ, Perlman DH. 2013. Extensive post-translational modification of active and inactivated forms of endogenous p53. Mol Cell Proteomics 13:1-17.
34. Donehower, LA. 2014. Insights into wildtype and mutant p53 functions provided by genetically engineered mice. Hum Mutat 35:715-727.
35. Donehower LA, Lozano G. 2009. 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer 9:831-841.
36. Elston R, Inman GJ. 2012. Crosstalk between p53 and TGF-β signalling. J Signal Transduct 2012:294097.
37. Emamzadah S, Tropia L, Halazonetis TD. 2011. Crystal structure of a multidomain human p53 tetramer bound to the natural CDKN1A (p21) p53-response element. Mol Cancer Res 9:1493-1499.
38. Endicott JA, Noble MEM, Johnson LN. 2012. The structural basis for control of eukaryotic protein kinases. Annu Rev Biochem 81:587-613.
39. Feng L, Hollstein M, Xu Y. 2006. Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence. Cell Cycle 5:2812-2819.
40. Feng L, Lin T, Uranishi H, Gu W, Xu Y. 2005. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol 25:5389-5395.
41. Ferreon JC, Lee CW, Arai M, Martinez-Yamout MA, Dyson HJ, Wright PE. 2009. Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2. Proc Natl Acad Sci USA 106:6591-6596.
42. Freeman JA, Espinosa JM. 2013. The impact of post-transcriptional regulation in the p53 network. Brief Funct Genomics 12:46-57.
43. Furihata M, Kurabayashl A, Matsumoto M, Sonobe H, Ohtsuki Y, Terao N, Kuwahara M, Shuin T. 2002. Frequent phosphorylation at serine 392 in overexpressed p53 protein due to missense mutation in carcinoma of the urinary tract. J Pathol 197:82-88.
44. Gardino AK, Yaffe MB. 2011. 14-3-3 proteins as signaling integration points for cell cycle control and apoptosis. Semin Cell Dev Biol 22:688-695.
45. Gillotin S, Yap D, Lu X. 2010. Mutation at Ser392 specifically sensitizes mutant p53H175 to mdm2-mediated degradation. Cell Cycle 9:1390-1398.
46. Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, Capaci V, Jordan L, Quinlan P, Thompson A, Mano M, Rosato A, et al. 2011. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 20:79-91.
47. Goh AM, Coffill CR, Lane DP. 2011. The role of mutant p53 in human cancer. J Pathol 223:116-126.
48. Gu B, Zhu W-G. 2012. Surf the post-translational modification network of p53 regulation. Int J Biol Sci 8:672-684.
49. Haupt S, di Agostino S, Mizrahi I, Alsheich-Bartok O, Voorhoeve M, Damalas A, Blandino G, Haupt Y. 2009. Promyelocytic leukemia protein is required for gain of function by mutant p53. Cancer Res 69:4818-4826.
50. Hock A, Vousden KH. 2010. Regulation of the p53 pathway by ubiquitin and related proteins. Int J Biochem Cell Biol 42:1618-1621.
51. Hollstein M, Sidransky D, Vogelstein B, Harris CC. 1991. p53 mutations in human cancers. Science 253:49-53.
52. Hoogervorst EM, Bruins W, Zwart E, van Oostrom CTM, van den Aardweg GJ, Beems RB, van den Berg J, Jacks T, van Steeg H, de Vries A. 2005. Lack of p53 Ser389 phosphorylation predisposes mice to develop 2-acetylaminofluorene-induced bladder tumors but not ionizing radiation-induced lymphomas. Cancer Res 65:3610-3616.
53. Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, Opravil S, Shiekhattar R, Bedford MT, Jenuwein T, Berger SL. 2007. p53 is regulated by the lysine demethylase LSD1. Nature 449:105-108.
54. Huang Y, Jeong JS, Okamura J, Sook-Kim M, Zhu H, Guerrero-Preston R, Ratovitski EA. 2012. Global tumor protein p53/p63 interactome: making a case for cisplatin chemoresistance. Cell Cycle 11:2367-2379.
55. Hupp TR, Lane DP. 1995. Two distinct signaling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner. J Biol Chem 270:18165-18174.
56. Iwabuchi K, Bartel PL, Li B, Marraccino R, Fields S. 1994. Two cellular proteins that bind to wild-type but not mutant p53. Proc Natl Acad Sci USA 91:6098-6102.
57. Jansson M, Durant ST, Cho E-C, Sheahan S, Edelmann M, Kessler B, La Thangue NB. 2008. Arginine methylation regulates the p53 response. Nat Cell Biol 10:1431-1439.
58. Jeffrey PD, Gorina S, Pavletich NP. 1995. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 267:1498-1502.
59. Jenkins LMM, Durell SR, Mazur SJ, Appella E. 2012. p53 N-terminal phosphorylation: a defining layer of complex regulation. Carcinogenesis 33:1441-1449.
60. K317R knock-in mouse thymocytes. Mol Cell Proteomics 7:716-727.
61. Jiang D, Brady CA, Johnson TM, Lee EY, Park EJ, Scott MP, Attardi LD. 2011. Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages. Proc Natl Acad Sci USA 108:17123-17128.
62. Kachirskaia I, Shi X, Yamaguchi H, Tanoue K, Wen H, Wang EW, Appella E, Gozani O. 2008. Role for 53BP1 tudor domain recognition of p53 dimethylated at lysine 382 in DNA damage signaling. J Biol Chem 283:34660-34666.
63. Kamada R, Nomura T, Anderson CW, Sakaguchi K. 2011. Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation. J Biol Chem 286:252-258.
64. Kato S, Han S-Y, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C. 2003. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100:8424-8429.
65. Keller DM, Zeng X, Wang Y, Zhang QH, Kapoor M, Shu H, Goodman R, Lozano G, Zhao Y, Lu H. 2001. A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol Cell 7:283-292.
66. Kim K, Jeong KW, Kim H, Choi J, Lu W, Stallcup MR, An W. 2012. Functional interplay between p53 acetylation and H1.2 phosphorylation in p53-regulated transcription. Oncogene 31:4290-4301.
67. Kleiblova P, Shaltiel IA, Benada J, Ševčík J, Pecháčková S, Pohlreich P, Voest EE, Dundr P, Bartek J, Kleibl Z, Medema RH, Macurek L. 2013. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint. J Cell Biol 201:511-521.
68. Krummel KA, Lee CJ, Toledo F, Wahl GM. 2005. The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc Natl Acad Sci USA 102:10188-10193.
69. Kruse J-P, Gu W. 2009a. MSL2 promotes Mdm2-independent cytoplasmic localization of p53. J Biol Chem 284:3250-3263.
70. Kruse J-P, Gu W. 2009b. Modes of p53 regulation. Cell 137:609-622.
71. Kulikov R, Winter M, Blattner C. 2006. Binding of p53 to the central domain of Mdm2 is regulated by phosphorylation. J Biol Chem 281:28575-28583.
72. Kurash JK, Lei H, Shen Q, Marston WL, Granda BW, Fan H, Wall D, Li E, Gaudet F. 2008. Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. Mol Cell 29:392-400.
73. Kurimchak A, Graña X. 2013. PP2A counterbalances phosphorylation of pRB and mitotic proteins by multiple CDKs: potential implications for PP2A disruption in cancer. Genes Cancer 3:739-748.
74. Lane DP, Cheok CF, Brown C, Madhumalar A, Ghadessy FJ, Verma C. 2010. Mdm2 and p53 are highly conserved from placozoans to man. Cell Cycle 9:540-547.
75. Lang GA, Iwakuma T, Suh Y-A, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G. 2004. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119:861-872.
76. Latronico AC, Pinto EM, Domenice S, Fragoso MCBV, Martin RM, Zerbini MC, Lucon AM, Mendonca BB. 2001. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab 86:4970-4973.
77. Lee CW, Ferreon JC, Ferreon ACM, Arai M, Wright PE. 2010. Graded enhancement of p53 binding to CREB-binding protein (CBP) by multisite phosphorylation. Proc Natl Acad Sci USA 107:19290-19295.
78. Lee JT, Gu W. 2010. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ 17:86-92.
79. Lee MK, Teoh WW, Phang BH, Tong WM, Wang ZQ, Sabapathy K. 2012. Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo. Cancer Cell 22:751-764.
80. Lee MK, Tong WM, Wang ZQ, Sabapathy K. 2011. Serine 312 phosphorylation is dispensable for wild-type p53 functions in vivo. Cell Death Differ 18:214-221.
81. Lehnertz B, Rogalski JC, Schulze FM, Yi L, Lin S, Kast J, Rossi FMV. 2011. p53-dependent transcription and tumor suppression are not affected in Set7/9-deficient mice. Mol Cell 43:673-680.
82. Lens SMA, Voest EE, Medema RH. 2010. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 10:825-841.
83. Leroy B, Fournier JL, Ishioka C, Monti P, Inga A, Fronza G, Soussi T. 2013. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res 41(Database issue):D962-D969.
84. Li AG, Piluso LG, Cai X, Gadd BJ, Ladurner AG, Liu X. 2007. An acetylation switch in p53 mediates holo-TFIID recruitment. Mol Cell 28:408-421.
85. Li D, Marchenko ND, Schulz R, Fischer V, Velasco-Hernandez T, Talos F, Moll UM. 2011. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Cancer Res 9:577-588.
86. Li M, Luo J, Brooks CL, Gu W. 2002. Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem 277:50607-50611.
87. Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, Baer R, Gu W. 2012. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149:1269-1283.
88. Li Y, Park J, Piao L, Kong G, Kim Y, Park KA, Zhang T, Hong J, Hur GM, Seok JH, Choi S-W, Yoo BC, et al. 2013. PKB-mediated PHF20 phosphorylation on Ser291 is required for p53 function in DNA damage. Cell Signal 25:74-84.
89. Lin T, Chao C, Saito S, Mazur SJ, Murphy ME, Appella E, Xu Y. 2005. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol 7:165-171.
90. Liou Y-C, Zhou XZ, Lu KP. 2011. Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins. Trends Biochem Sci 36:501-514.
91. Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q, Shi XB, deVere White RW, Gao AC. 2013. Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate 73:418-427.
92. Liu Q, Kaneko S, Yang L, Feldman RI, Nicosia SV, Chen J, Cheng JQ. 2004. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem 279:52175-52182.
93. Loughery J, Meek D. 2013. Switching on p53: an essential role for protein phosphorylation? BioDiscovery 8:1-20.
94. Lozano G. 2007. The oncogenic roles of p53 mutants in mouse models. Curr Opin Genet Dev 17:66-70.
95. Lu X, Nguyen TA, Moon SH, Darlington Y, Sommer M, Donehower LA. 2008. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev 27:123-135.
96. Lukashchuk N, Vousden KH. 2007. Ubiquitination and degradation of mutant p53. Mol Cell Biol 27:8284-8295.
97. MacLaine NJ, Hupp TR. 2009. The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathway. Aging (Albany NY) 1:490-502.
98. MacPherson D, Kim J, Kim T, Rhee BK, van Oostrom CT, DiTullio RA, Jr., Venere M, Halazonetis TD, Bronson R, De Vries A, Fleming M, Jacks T. 2004. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J 23:3689-3699.
99. Maki CG. 1999. Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. J Biol Chem 274:16531-16535.
100. Mantovani F, Tocco F, Girardini J, Smith P, Gasco M, Lu X, Crook T, Del Sal G. 2007. The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat Struct Mol Biol 14:912-920.
101. Matsumoto M, Furihata M, Kurabayashi A, Ohtsuki Y. 2004a. Phosphorylation state of tumor-suppressor gene p53 product overexpressed in skin tumors. Oncol Rep 12:1039-1043.
102. Matsumoto M, Furihata M, Kurabayashi A, Sasaguri S, Araki K, Hayashi H, Ohtsuki Y. 2004b. Prognostic significance of serine 392 phosphorylation in overexpressed p53 protein in human esophageal squamous cell carcinoma. Oncology 67:143-150.
103. Matsumoto M, Furihata M, Ohtsuki Y. 2006. Posttranslational phosphorylation of mutant p53 protein in tumor development. Med Mol Morphol 39:79-87.
104. Meek DW. 2009. Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 9:714-723.
105. Meek DW, Anderson CW. 2009. Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol 1:a000950.
106. Mellert H, Sykes SM, Murphy ME, McMahon SB. 2007. The ARF/oncogene pathway activates p53 acetylation within the DNA binding domain. Cell Cycle 6:1304-1306.
107. Melnikova VO, Santamaria AB, Bolshakov SV, Ananthaswamy HN. 2003. Mutant p53 is constitutively phosphorylated at Serine 15 in UV-induced mouse skin tumors: involvement of ERK1/2 MAP kinase. Oncogene 22:5958-5966.
108. Menendez D, Inga A, Resnick MA. 2009. The expanding universe of p53 targets. Nat Rev Cancer 9:724-737.
109. Midgley CA, Lane DP. 1997. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15:1179-1189.
110. Minamoto T, Buschmann T, Habelhah H, Matusevich E, Tahara H, Boerresen-Dale A-L, Harris C, Sidransky D, Ronai Z. 2001. Distinct pattern of p53 phosphorylation in human tumors. Oncogene 20:3341-3347.
111. Muller PAJ, Vousden KH, Norman JC. 2011. p53 and its mutants in tumor cell migration and invasion. J Cell Biol 192:209-218.
112. Muller PAJ, Vousden KH. 2013. p53 mutations in cancer. Nat Cell Biol 15:2-8.
113. Nagata Y, Anan T, Yoshida T, Mizukami T, Taya Y, Fujiwara T, Kato H, Saya H, Nakao M. 1999. The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association. Oncogene 18:6037-6049.
114. Noon AT, Goodarzi AA. 2011. 53BP1-mediated DNA double strand break repair: insert bad pun here. DNA Repair (Amst) 10:1071-1076.
115. Odell AF, Odell LR, Askham JM, Alogheli H, Ponnambalam S, Hollstein M. 2013. A novel p53 mutant found in iatrogenic urothelial cancers is dysfunctional and can be rescued by a second-site global suppressor mutation. J Biol Chem 288:16704-16714.
116. Okaichi K, Nose K, Kotake T, Izumi N, Kudo T. 2011. Phosphorylation of p53 modifies sensitivity to ionizing radiation. Anticancer Res 31:2255-2258.
117. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. 2004. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119:847-860.
118. Ou Y-H, Chung P-H, Sun T-P, Shieh S-Y. 2005. p53 C-terminal phosphorylation by CHK1 and CHK2 participates in the regulation of DNA-damage-induced C-terminal acetylation. Mol Biol Cell 16:1684-1695.
119. Park S, Kim D, Dan HC, Chen H, Testa JR, Cheng JQ. 2012. Identification of Akt interaction protein PHF20/TZP that transcriptionally regulates p53. J Biol Chem 287:11151-11163.
120. Patel DJ, Wang Z. 2013. Readout of epigenetic modifications. Annu Rev Biochem 82:81-118.
121. Perez RE, Knights CD, Sahu G, Catania J, Kolukula VK, Stoler D, Graessmann A, Ogryzko V, Pishvaian M, Albanese C, Avantaggiati ML. 2010. Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway. J Cell Physiol 225:394-405.
122. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. 2007. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622-629.
123. Pfeifer GP, Hainaut P. 2011. Next-generation sequencing: emerging lessons on the origins of human cancer. Curr Opin Oncol 23:62-68.
124. Pietenpol JA, Tokino T, Thiagalingam S, el-Deiry WS, Kinzler KW, Vogelstein B. 1994. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci USA 91:1998-2002.
125. Pietsch EC, Leu JI-J, Frank A, Dumont P, George DL, Murphy ME. 2007. The tetramerization domain of p53 is required for efficient BAK oligomerization. Cancer Biol Ther 6:1576-1583.
126. Puca R, Nardinocchi L, Givol D, D'Orazi G. 2009. Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells. Oncogene 29:4378-4387.
127. Ray D, Murphy KR, Gal S. 2012. The DNA binding and accumulation of p53 from breast cancer cell lines and the link with serine 15 phosphorylation. Cancer Biol Ther 13:848-857.
128. Resnick MA, Inga A. 2003. Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci USA 100:9934-9939.
129. Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, DeLacerda L, Rabin M, Cadwell C, Sampaio G, Cat I, Stratakis CA, et al. 2001. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 98:9330-9335.
130. Riley T, Sontag E, Chen P, Levine A. 2008. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9:402-412.
131. Rinn JL, Huarte M. 2011. To repress or not to repress: This is the guardian's question. Trends Cell Biol 21:344-353.
132. Rodriguez OC, Choudhury S, Kolukula V, Vietsch EE, Catania J, Preet A, Reynoso K, Bargonetti J, Wellstein A, Albanese C, Avantaggiati ML. 2012. Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle 11:4436-4446.
133. Rokudai S, Laptenko O, Arnal SM, Taya Y, Kitabayashi I, Prives C. 2013. MOZ increases p53 acetylation and premature senescence through its complex formation with PML. Proc Natl Acad Sci USA 110:3895-3900.
134. Roy S, Musselman CA, Kachirskaia I, Hayashi R, Glass KC, Nix JC, Gozani O, Appella E, Kutateladze TG. 2010. Structural insight into p53 recognition by the 53BP1 tandem Tudor domain. J Mol Biol 398:489-496.
135. Sabapathy K. 2012. Role of the JNK pathway in human diseases. Prog Mol Biol Transl Sci 106:145-169.
136. Saito S, Yamaguchi H, Higashimoto Y, Chao C, Xu Y, Fornace AJ, Jr., Appella E, Anderson CW. 2003. Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J Biol Chem 278:37536-37544.
137. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E. 1998. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12:2831-2841.
138. Sakaguchi K, Sakamoto H, Lewis MS, Anderson CW, Erickson JW, Appella E, Xie D. 1997. Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry 36:10117-10124.
139. Schumacher B, Mondry J, Thiel P, Weyand M, Ottmann C. 2010. Structure of the p53 C-terminus bound to 14-3-3: implications for stabilization of the p53 tetramer. FEBS Lett 584:1443-1448.
140. Serrano MA, Li Z, Dangeti M, Musich PR, Patrick S, Roginskaya M, Cartwright B, Zou Y. 2013. DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate homologous recombination DNA repair. Oncogene 32:2452-2462.
141. Shieh SY, Ikeda M, Taya Y, Prives C. 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325-334.
142. Shiraishi K, Kato S, Han S-Y, Liu W, Otsuka K, Sakayori M, Ishida T, Takeda M, Kanamaru R, Ohuchi N, Ishioka C. 2004. Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem 279:348-355.
143. Slee EA, Benassi B, Goldin R, Zhong S, Ratnayaka I, Blandino G, Lu X. 2010. Phosphorylation of Ser312 contributes to tumor suppression by p53 in vivo. Proc Natl Acad Sci USA 107:19479-19484.
144. Sluss HK, Armata H, Gallant J, Jones SN. 2004. Phosphorylation of serine 18 regulates distinct p53 functions in mice. Mol Cell Biol 24:976-984.
145. Sluss HK, Gannon H, Coles AH, Shen Q, Eischen CM, Jones SN. 2010. Phosphorylation of p53 serine 18 upregulates apoptosis to suppress Myc-induced tumorigenesis. Mol Cancer Res 8:216-222.
146. Song H, Hollstein M, Xu Y. 2007. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 9:573-580.
147. Stebbing J, Lit LC, Zhang H, Darrington RS, Melaiu O, Rudraraju B, Giamas G. 2013. The regulatory roles of phosphatases in cancer. Oncogene. [Epub ahead of print.]
148. Strebhardt K. 2010. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 9:643-660.
149. Sugikawa E, Yazaki N, Tsunoda S, Nakanishi N, Ohashi M. 1999. Inhibition of mutant p53 phosphorylation at serine 15 or serine 315 partially restores the function of wild-type p53. Biochem Biophys Res Commun 261:256-263.
150. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. 2008. Acetylation is indispensable for p53 activation. Cell 133:612-626.
151. INK4a loss. Genes Dev 22:1337-1344.
152. Teufel DP, Bycroft M, Fersht AR. 2009. Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2. Oncogene 28:2112-2118.
153. Theuerkorn M, Fischer G, Schiene-Fischer C. 2011. Prolyl cis/trans isomerase signalling pathways in cancer. Curr Opin Pharmacol 11:281-287.
154. Timofeev O, Schlereth K, Wanzel M, Braun A, Nieswandt B, Pagenstecher A, Rosenwald A, Elsässer H-P, Stiewe T. 2013. p53 DNA binding cooperativity is essential for apoptosis and tumor suppression in vivo. Cell Rep 3:1512-1525.
155. Toledo F, Wahl GM. 2006. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6:909-923.
156. Trojer P, Li G, Sims RJ, 3rd, Vaquero A, Kalakonda N, Boccuni P, Lee D, Erdjument-Bromage H, Tempst P, Nimer SD, Wang Y-H, Reinberg D. 2007. L3MBTL1, a histone-methylation-dependent chromatin lock. Cell 129:915-928.
157. Ullrich S, Sakaguchi K, Lees-Miller S, Fiscella M, Mercer W, Anderson C, Appella E. 1993. Phosphorylation at Ser-15 and Ser-392 in mutant p53 molecules from human tumors is altered compared to wild-type p53. Proc Natl Acad Sci USA 90:5954-5958.
158. Valente LJ, Gray DHD, Michalak EM, Pinon-Hofbauer J, Egle A, Scott CL, Janic A, Strasser A. 2013. p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep 3:1339-1345.
159. Valenti F, Fausti F, Biagioni F, Shay T, Fontemaggi G, Domany E, Yaffe MB, Strano S, Blandino G, Di Agostino S. 2011. Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. Cell Cycle 10:4330-4340.
160. van Dieck J, Teufel DP, Jaulent AM, Fernandez-Fernandez MR, Rutherford TJ, Wyslouch-Cieszynska A, Fersht AR. 2009. Posttranslational modifications affect the interaction of S100 proteins with tumor suppressor p53. J Mol Biol 394:922-930.
161. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr., Kinzler KW. 2013. Cancer genome landscapes. Science 339:1546-1558.
162. Vousden KH, Prives C. 2009. Blinded by the light: the growing complexity of p53. Cell 137:413-431.
163. Wade M, Li Y-C, Wahl GM. 2013. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 13:83-96.
164. Wade M, Wang YV, Wahl GM. 2009. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 20:299-309.
165. Warnock LJ, Knox A, Mee TR, Raines SA, Milner J. 2008. Influence of tetramerisation on site-specific post-translational modifications of p53: comparison of human and murine p53 tumor suppressor protein. Cancer Biol Ther 7:1481-1489.
166. Warnock LJ, Raines SA, Milner J. 2011. Aurora A mediates cross-talk between N- and C-terminal post-translational modifications of p53. Cancer Biol Ther 12:1059-1068.
167. Waterman MJF, Stavridi ES, Waterman JLF, Halazonetis TD. 1998. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat Genet 19:175-178.
168. West LE, Gozani O. 2011. Regulation of p53 function by lysine methylation. Epigenomics 3:361-369.
169. West LE, Roy S, Lachmi-Weiner K, Hayashi R, Shi X, Appella E, Kutateladze TG, Gozani O. 2010. The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine 382 to target gene repression. J Biol Chem 285:37725-37732.
170. Wiech M, Olszewski MB, Tracz-Gaszewska Z, Wawrzynow B, Zylicz M, Zylicz A. 2012. Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2. PLoS One 7:e51426.
171. Xu Y, Xu C, Price BD. 2012. Mechanistic links between ATM and histone methylation codes during DNA repair. Prog Mol Biol Transl Sci 110:263-288.
172. Yakovlev VA, Bayden AS, Graves PR, Kellogg GE, Mikkelsen RB. 2010. Nitration of the tumor suppressor protein p53 at tyrosine 327 promotes p53 oligomerization and activation. Biochemistry 49:5331-5339.
173. Yang X, Li H, Zhou Z, Wang W-H, Deng A, Andrisani O, Liu X. 2009. Plk1-mediated phosphorylation of Topors regulates p53 stability. J Biol Chem 284:18588-18592.
174. 392 phosphorylation regulates the oncogenic function of mutant p53. Cancer Res 64:4749-4754.
175. You JS, Jones PA. 2012. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 22:9-20.
176. Zannini L, Buscemi G, Kim J-E, Fontanella E, Delia D. 2012. DBC1 phosphorylation by ATM/ATR inhibits SIRT1 deacetylase in response to DNA damage. J Mol Cell Biol 4:294-303.
177. Zerbini LF, Wang Y, Correa RG, Cho J-Y, Libermann TA. 2005. Blockage of NF-κB induces serine 15 phosphorylation of mutant p53 by JNK kinase in prostate cancer cells. Cell Cycle 4:1247-1253.
178. Zhu Y-H, Bulavin DV. 2012. Wip1-dependent signaling pathways in health and diseases. Prog Mol Biol Transl Sci 106:307-325.
179. Zilfou JT, Lowe SW. 2009. Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol 1:a001883.